logo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

Business Wire08-06-2025
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks.
SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4.
'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.'
'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.'
About SOLVE FSHD
SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit https://www.solvefshd.com.
Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit https://www.modalistx.com/en/.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Crystal Creek by LGI Homes Brings Premium Townhome Living to Spring Hill, TN
Crystal Creek by LGI Homes Brings Premium Townhome Living to Spring Hill, TN

Business Upturn

time7 hours ago

  • Business Upturn

Crystal Creek by LGI Homes Brings Premium Townhome Living to Spring Hill, TN

SPRING HILL, Tenn., July 11, 2025 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced the opening of Crystal Creek, its newest community in the Nashville market. This community offers a lineup of charming townhomes with included upgrades and easy access to all that the area has to offer. Conveniently located in Spring Hill, homeowners at Crystal Creek are well-positioned near Saturn Parkway and I-65, providing quick access to major employers such as GM Spring Hill, as well as local shopping and dining options. 'Just 30 miles south of Nashville, Spring Hill is one of Middle Tennessee's most desirable places to live, where small-town charm meets modern convenience. From charming local boutiques to national retailers, plus a growing dining scene, Crystal Creek in Spring Hill has everything you need, just minutes away,' said Chris Welpott, Vice President of Sales for Tennessee. 'Crystal Creek by LGI Homes offers exceptional value and opportunity with spacious floor plans, a low-maintenance lifestyle, and designer finishes included in every home. Whether you're buying your first home or upgrading to your forever one, Crystal Creek offers the perfect community for every stage of life.' Crystal Creek offers plenty of opportunities for fun with its impressive amenities. Head to the park where children can run and play, or use the multi-purpose fields to start a community soccer league. One of the most impressive features are the shaded walking trails that run throughout the community and connects to City of Spring Hill Greenway. LGI Homes is building two-story, three-bedroom, two-and-a-half bathroom townhomes that range from 1,794 to 1,952 square feet. Equipped with our CompleteHome Plus™ package, every home includes upgraded features at no extra cost. Gorgeous exteriors, chef-ready kitchens with Whirlpool® appliances and smart-home technology are just a few premier features that new homeowners can look forward to upon moving in. These exceptional homes include expansive primary suites that are the perfect place to unwind after a long day and secondary bedrooms that are ready to be used for your family's unique needs. Move-in ready homes within this community start in the mid-$400s. Interested buyers can schedule an appointment or stop by the information center daily from 11:00 am to 7:00 pm. To schedule a tour or for additional information, please call (844) 581-1287 ext 195 or visit About LGI Homes Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. As one of America's fastest growing companies, LGI Homes has closed over 75,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek's list of the World's Most Trustworthy Companies. LGI Homes' commitment to excellence extends to its more than 1,000 employees, earning the Company numerous workplace awards at the local, state and national level, including the Top Workplaces USA 2025 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company's website at MEDIA CONTACT:Rachel Eaton (281) 362-8998 ext. 2560

Central Pacific Financial Corp. Announces Conference Call to Discuss Second Quarter 2025 Financial Results
Central Pacific Financial Corp. Announces Conference Call to Discuss Second Quarter 2025 Financial Results

Business Wire

time10 hours ago

  • Business Wire

Central Pacific Financial Corp. Announces Conference Call to Discuss Second Quarter 2025 Financial Results

HONOLULU--(BUSINESS WIRE)--Central Pacific Financial Corp. (NYSE: CPF), parent company of Central Pacific Bank, will release its second quarter 2025 earnings on July 25, 2025, before the open of the New York Stock Exchange. Management will review the results by conference call and live audio webcast beginning at 2:00 p.m. Eastern Time (8:00 a.m. Hawaii Time) on July 25, 2025. Interested parties may listen to the conference by calling 1-800-715-9871 (conference ID: 6299769), or by listening to the webcast on the company's investor relations website at A replay of the call will be available through August 24, 2025 by dialing 1-800-770-2030 (conference ID: 6299769) and on the company's website. About Central Pacific Financial Corp. Central Pacific Financial Corp. is a Hawaii-based bank holding company with approximately $7.41 billion in assets as of March 31, 2025. Central Pacific Bank, its primary subsidiary, operates 27 branches and 55 ATMs in the State of Hawaii. For additional information, please visit the Company's website at: Equal Housing Lender Member FDIC NYSE Listed CPF

Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit
Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit

Business Wire

time10 hours ago

  • Business Wire

Kirby McInerney LLP Urges Investors in DoubleVerify Holdings, Inc. (DV) to Inquire About Their Rights in Class Action Lawsuit

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors of the July 21, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired DoubleVerify Holdings, Inc. ('DoubleVerify' or the 'Company') (NYSE:DV) securities during the period from November 10, 2023, through February 27, 2025 ('the Class Period'). [ LEARN MORE ABOUT THE CLASS ACTION ] On February 28, 2024, DoubleVerify issued lower revenue growth expectations for the first quarter of 2024 due to 'a slow start by brand advertisers and a slow ramp by recently signed new large customers.' On this news, the price of DoubleVerify shares declined by $8.25 per share, or approximately 21%, from $39.24 per share on February 28, 2024, to close at $30.89 on February 29, 2024. On May 7, 2024, in connection with its first quarter 2024 earnings report, DoubleVerify surprised analysts by cutting its full-year 2024 revenue outlook due to customers that were pulling back on their ad spending. On this news, the price of DoubleVerify shares declined by $11.79 per share, or approximately 38%, from $30.57 per share on May 7, 2024, to close at $18.78 on May 8, 2024. Then, on February 27, 2025, when DoubleVerify reported lower-than-expected fourth quarter 2024 sales and earnings due in part to reduced customer spending, DoubleVerify also disclosed that the shift of ad dollars from open exchanges to closed platforms was negatively impacting the Company. On this news, the price of DoubleVerify shares declined by $7.83, or approximately 36%, from $21.73 per share on February 27, 2025, to close at $13.90 on February 28, 2025. Finally, on March 28, 2025, market research company Adalytics Research, LLC released a report claiming that DoubleVerify's web advertisement verification and fraud protection services are ineffective, and that DoubleVerify customers are regularly billed for ad impressions served to declared bots operating out of known data center server farms. On the same day, The Wall Street Journal reported that DoubleVerify regularly misses detection of nonhuman traffic in contradiction to the Company's claims that it helps brand avoid serving ads to nonhuman bot accounts. If you purchased or otherwise acquired DoubleVerify securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@ or fill out the form below, to discuss your rights or interests with respect to these matters without any cost to you. [ CONTACT FORM ] Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP's website. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store